Quanti9TM & QuantiGalTM

Quanti9TM & QuantiGalTM, a prognostic prediction kit for cardiovascular diseases

ELISA-based Quanti9 and QuantiGal predict the risk of heart failure in patients with acute myocardial infarction. Heart failure is a fatal disease from which 50% of patients die within 5 years, and the prognosis prediction of the disease is important.

MMP9 is a 92 kDa matrix metalloproteinase family protein secreted by a wide range of cells, such as neutrophils, macrophage or vascular smooth cells. These family proteins play an important role in tissue remodeling of extracellular matrix and plaque degradation. MMP9 has the potential to predict and diagnose cardiac remodeling. MMP9 is a good predictor for left ventricular remodeling leading to Heart Failure after a first acute myocardial infarction.

NGAL is a robust biomarker predictor of heart failure after acute myocardial infarction. Despite its high diagnosis value for kidney injuries, scientific studies have shown that NGAL participates in vascular remodeling and in the development of inflammatory reactions during the course of Heart Failure, increased with a first acute myocardial infarction.

Predicting the risk of heart failure in patients with acute myocardial infarction

Conventional tests cannot identify high-risk patients among those with early-stage acute myocardial infarction. Quanti9 and QuantiGal overcome these limits and can detect high-risk patients with early stage, acute myocardial infarction. As a result patients can be prescribed preventative medicine which can results in better patient prognosis.


Biomarkers that have been proven for many years can predict risk before the outbreaks of heart failure symptoms, and are characterized by higher accuracy and prediction than other companies’ products.

High accuracy
with proven biomarkers

High predictability
with years of development

Early prediction
before the outbreaks of
heart failure symptoms